Alison MasonHead of Upstream Development at Ipsen Biopharm
Alison joined IPSEN as Head of Upstream Development in 2018 and has around 20 years’ industrial experience, working previously at MedImmune and Lonza Biologics. Her work experience covers both microbial and mammalian expression to develop products from Neurotoxins to Monoclonal Antibodies. Alison’s expertise lies in development of platform processes to facilitate product progress through the clinical pipeline and to simplify and streamline technology transfer and scale-up. She is also interested in cellular metabolism, implementation of high throughput scale-down bioreactors and improved process monitoring. Alison holds a BSc(Hons) in Microbiology from the University of Manchester.